WO2023111725 - SARS-COV-2 VACCINES
National phase entry is expected:
Publication Number
WO/2023/111725
Publication Date
22.06.2023
International Application No.
PCT/IB2022/061202
International Filing Date
21.11.2022
Title **
[English]
SARS-COV-2 VACCINES
[French]
VACCINS ANTI-SARS-COV-2
Applicants **
JANSSEN PHARMACEUTICALS, INC.
Inventors
JURASZEK, Jaroslaw
DE WILDE, Adriaan, Hugo
Priority Data
63/265,379
14.12.2021
US
63/266,381
04.01.2022
US
22158884.1
25.02.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2832 | |
| EPO | Filing, Examination, Granting | 14896 | |
| Japan | Filing, Examination, Granting | 2490 | |
| South Korea | Filing, Examination, Granting | 2722 | |
| USA | Filing, Examination, Granting | 8740 |
Total:
31,680
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to isolated nucleic and/or recombinant nucleic acid encoding a coronavirus S protein, and to the coronavirus S proteins, as well as to the use of the nucleic acids and/or proteins thereof in vaccines.[French]
La présente invention concerne un acide nucléique isolé et/ou nucléique recombinant codant pour une protéine S du coronavirus, et les protéines S du coronavirus, ainsi que l'utilisation des acides nucléiques et/ou des protéines associées dans des vaccins.